Skip to main content
USFDA Form 483 Observations on Cleaning and Housekeeping: How Indian Pharma Plants Can Avoid Them
Quick answer: Cleaning problems are among the most frequent USFDA Form 483 observations. In FY2025, “cleaning, sanitizing and maintenance deficiencies” (21 CFR 211.67(a)) was the 5th most cited drug GMP observation, with 95 citations, and “cleaning procedures not established or not followed” (211.67(b)) ranked 8th, with 70. Most come down to missing or unfollowed written procedures, incomplete cleaning logs and untrained staff, and US rules apply to cleaning contractors too.
What is a USFDA Form 483?
A Form 483 is the list of observations an FDA investigator hands a plant at the end of an inspection when they see conditions that may break US drug GMP rules (21 CFR Part 211). It is not a final verdict, but plants are expected to respond with corrective actions. Unresolved or repeat observations can lead to a warning letter, import alerts and lost US business.
For India’s USFDA-approved plants, especially the large export hubs in Hyderabad, Goa, Gujarat and Bengaluru, cleaning is one of the most visible areas an investigator checks on the floor.
What do US GMP rules say about cleaning and sanitation?
The cleaning rules sit in 21 CFR Part 211, the US GMP regulation for finished pharmaceuticals:
Section | What it requires |
|---|---|
211.56(a) | Buildings kept “in a clean and sanitary condition”, free of pests, with trash disposed of promptly |
211.56(b) | Written procedures assigning sanitation responsibility, with cleaning schedules, methods and materials |
211.56(c) | Written procedures for the use of cleaning agents and pesticides, designed to prevent contamination |
211.56(d) | Sanitation procedures apply to work done by contractors and temporary staff |
211.67(a) | Equipment “cleaned, maintained, and sanitized at appropriate intervals” to prevent contamination |
211.67(b) | Written, followed cleaning procedures covering responsibility, schedules, methods and inspection before use |
211.67(c) | Records of cleaning, sanitizing, maintenance and inspection kept |
211.182 | Equipment cleaning and use logs, in date order, signed or initialled by the person doing the work |
211.28 | Staff wear clean clothing suited to their duties and follow good sanitation habits |
211.42(c)(10)(v) | Aseptic areas need “a system for cleaning and disinfecting the room and equipment” |
Note clause 211.56(d): if you outsource cleaning, your contractor’s crew must follow the same sanitation procedures as your own staff, and investigators can cite the plant for their gaps.
What are the most common FDA 483 observations linked to cleaning?
Two of FDA’s top 10 drug GMP citations in FY2025 were directly about cleaning, and the top three often involve cleaning procedures too:
FY2025 rank | Citation | Observation | Times cited |
|---|---|---|---|
1 | 211.22(d) | Procedures not in writing or not followed (quality unit) | 243 |
2 | 211.192 | Inadequate investigation of discrepancies and failures | 164 |
3 | 211.100(a) | Absence of adequate written procedures | 162 |
5 | 211.67(a) | Cleaning, sanitizing and maintenance deficiencies | 95 |
8 | 211.67(b) | Cleaning procedures not established or not followed | 70 |
9 | 211.113(b) | Sterile product contamination control procedures | 68 |
Source: GMP Insiders analysis of FDA’s FY2025 inspection observations.
For sterile manufacturers, a 2024 review of FDA observations found cleanroom cleaning and disinfection processes that were not validated, weak cleaning validation, and gaps in environmental monitoring. One warning letter it cited faulted a firm for not considering the operators who performed cleaning as a possible contamination source.
In practice, cleaning observations usually fall into a few patterns:
- No written procedure, or one that isn’t followed on the floor
- Incomplete or back-filled logs: missing signatures, dates or times
- Visible residue, dust or pests in production, storage or support areas
- Untrained or ungowned cleaners, including contractors
- Disinfection not validated, or no sporicide in aseptic areas
- No pre-use check that equipment is clean
How do you prevent cleaning-related 483 observations?
Typical observation | Rule | Fix |
|---|---|---|
No written cleaning or sanitation procedure for an area or machine | 211.56(b), 211.67(b) | Written SOP for every area and major equipment: who, how often, method, agents, inspection before use |
SOP exists but floor practice differs | 211.22(d), 211.67(b) | Train to the SOP, observe crews on the floor, update the SOP when practice changes |
Logs incomplete, back-dated or unsigned | 211.67(c), 211.182 | Sign and time at the point of cleaning; supervisor review every shift; no blank fields |
Dust, residue or pests found during walk-through | 211.56(a) | Scheduled high-level and periodic deep cleans; documented pest control; prompt waste removal |
Contractor cleaners not trained on site SOPs | 211.56(d), 211.28 | Contractor crews trained and qualified on your SOPs, with records in your files |
Aseptic area disinfection not validated or no sporicide | 211.42(c)(10)(v), 211.113(b) | Validated disinfectant rotation with a sporicide, supported by environmental monitoring |
Equipment used without a clean check | 211.67(b) | “Cleaned / to be cleaned” status labels and a recorded pre-use check |
Cleaning not considered in investigations | 211.192 | Include cleaning records and cleaning staff in every contamination investigation |
Cleaning readiness checklist before a USFDA inspection
- Every area and major machine has a current, approved cleaning SOP
- Cleaning logs for the last 6–12 months are complete, signed, dated and in order
- Equipment status labels are current on every machine
- Disinfectant rotation and sporicide schedule are documented and followed
- Cleaning staff, including contractors, have up-to-date training and gowning records
- High-level areas, drains, corners and utility rooms have had a recent deep clean
- Pest control records and service reports are filed
- Waste removal is on schedule, with no build-up in any area
- Self-inspection has covered sanitation, with findings closed
- Cleaning records are linked into recent deviations and investigations
How PinkClean helps USFDA-approved plants stay inspection-ready
Because US rules hold the plant responsible for its cleaning contractor’s work (21 CFR 211.56(d)), the contractor you choose matters. PinkClean is an ISO-certified company and a member of the Contamination Control Society of India (CCSI), serving pharma plants in Bangalore, Hyderabad, Goa and Kochi.
- Crews trained on your SOPs before they start, with training records for your files
- Point-of-cleaning sign-off and supervisor checks, so logs stand up to scrutiny
- Pre-inspection deep cleans of high-level areas, drains, utilities and warehouses
- Cleanroom cleaning to your disinfectant rotation and sporicide schedule
- Factory and industrial deep cleaning planned around production
Our projects include ISRO SHAR, RenewSys, MANN+HUMMEL and Bangalore Pharmaceutical & Research Laboratory (BPRL). Preparing for Indian inspections too? Read our Revised Schedule M cleaning checklist.
Frequently asked questions
What is an FDA Form 483?
A Form 483 is a list of inspection observations an FDA investigator gives a drug plant at the end of an inspection when conditions may violate US GMP rules in 21 CFR Part 211. The plant is expected to respond with corrective actions.
What is 21 CFR 211.67?
21 CFR 211.67 is the US GMP rule on equipment cleaning and maintenance. It requires equipment to be cleaned, maintained and sanitized at appropriate intervals, under written procedures, with records kept.
How common are cleaning observations in FDA inspections?
Very common. In FY2025, 21 CFR 211.67(a) on cleaning, sanitizing and maintenance was the 5th most cited drug GMP observation (95 times), and 211.67(b) on cleaning procedures ranked 8th (70 times).
Do FDA sanitation rules apply to cleaning contractors?
Yes. 21 CFR 211.56(d) says sanitation procedures apply to work performed by contractors and temporary employees, as well as full-time staff.
What happens if a 483 observation is not fixed?
Unresolved or repeat observations can lead to an FDA warning letter, import alerts and loss of US market access for the plant’s products.
How can a pharma plant avoid cleaning-related 483s?
Keep written SOPs for every area and machine, sign cleaning logs at the point of cleaning, train all cleaners including contractors, validate disinfection in aseptic areas and deep clean high-level and hidden areas regularly.
Get your plant inspection-ready
PinkClean, a CCSI member and ISO-certified company, helps USFDA and WHO-GMP plants in Bangalore, Hyderabad, Goa and Kochi keep cleaning audit-ready. Book a free site assessment before your next inspection.
📞 Bangalore: 96065 10235 · Mangalore: 91084 44692 · 🌐 pinkcleanindia.com
This article is general guidance, not regulatory advice. Always follow your QA team and the official regulations.
Sources
- 21 CFR Part 211, current good manufacturing practice for finished pharmaceuticals (text)
- FY2025 FDA inspection observations – GMP Insiders
- 2024 trends in FDA observations for sterile drug manufacturers – Pharmaceutical Online
